Trupanion (NASDAQ:TRUP) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Thursday.
Other research analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Trupanion from a “buy” rating to a “hold” rating in a report on Thursday, February 15th. Northland Securities reissued a “buy” rating and issued a $38.00 target price on shares of Trupanion in a report on Thursday, February 8th. Stifel Nicolaus reissued a “buy” rating and issued a $34.00 target price (up from $33.00) on shares of Trupanion in a report on Wednesday, February 14th. Cowen reissued an “outperform” rating and issued a $38.00 target price (up from $32.00) on shares of Trupanion in a report on Wednesday, February 14th. Finally, ValuEngine raised shares of Trupanion from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Trupanion has a consensus rating of “Buy” and an average target price of $35.57.
Shares of TRUP opened at $27.74 on Thursday. The company has a quick ratio of 1.89, a current ratio of 1.89 and a debt-to-equity ratio of 0.19. Trupanion has a 1 year low of $14.87 and a 1 year high of $37.13. The company has a market cap of $864.68, a price-to-earnings ratio of -396.29 and a beta of 0.57.
In other Trupanion news, Director Murray B. Low sold 3,000 shares of Trupanion stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $28.42, for a total transaction of $85,260.00. Following the completion of the transaction, the director now directly owns 194,281 shares of the company’s stock, valued at $5,521,466.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Darryl Rawlings sold 3,500 shares of Trupanion stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $28.42, for a total transaction of $99,470.00. Following the transaction, the insider now directly owns 1,379,476 shares of the company’s stock, valued at $39,204,707.92. The disclosure for this sale can be found here. Insiders have sold 21,500 shares of company stock valued at $642,465 over the last ninety days. 31.24% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the business. First Mercantile Trust Co. purchased a new position in Trupanion during the fourth quarter worth $129,000. JPMorgan Chase & Co. purchased a new position in Trupanion during the third quarter worth $143,000. Advisor Group Inc. purchased a new position in Trupanion during the fourth quarter worth $182,000. PEAK6 Investments L.P. purchased a new position in Trupanion during the fourth quarter worth $289,000. Finally, Arrowstreet Capital Limited Partnership purchased a new position in Trupanion during the fourth quarter worth $298,000. 74.81% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This story was posted by Week Herald and is the sole property of of Week Herald. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://weekherald.com/2018/04/21/bidaskclub-upgrades-trupanion-trup-to-hold.html.
Trupanion Company Profile
Trupanion, Inc, together with its subsidiaries, provides medical insurance for cats and dogs on monthly subscription basis in the United States, Canada, and Puerto Rico. The company operates through Subscription Business and Other Business segments. It serves pet owners and veterinarians through third-party referrals and online member acquisition channels.
Receive News & Ratings for Trupanion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trupanion and related companies with MarketBeat.com's FREE daily email newsletter.